Yazarlar : Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J.

Yayın : Blood.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22327226

Konu : Kemik İliği Nakli

Literatür İçeriği :  

Abstract

Approximately one-third of patients with an indication for HCT have a human leukocyte antigen (HLA) matched related donor (MRD) available to them. For the remaining patients, a matched unrelated donor (MUD) is an alternative. Prior studies comparing MRD and MUD HCT provide conflicting results, and the relative efficacy of MRD and MUD transplantation is an area of active investigation. To address this issue, we analyzed outcomes of 2,223 adult AML patients who underwent allogeneic HCT between 2002 and 2006 (MRD, n=624; 8/8 HLA locus matched MUD, n=1193; 7/8 MUD, n=406). The 100-day cumulative incidence of grades B-D acute graft-versus-host disease was significantly lower in MRD HCT recipients than 8/8 MUD and 7/8 MUD HCT recipients (33%, 51%, and 53%, respectively; p<.001). In multivariate analysis, 8/8 MUD HCT recipients had a similar survival rate compared to MRD HCT recipients (relative risk [RR], 1.03; p=0.62). 7/8 MUD HCT recipients had higher early mortality than MRD HCT recipients (RR, 1.40; p<.001), but beyond six months post HCT, their survival rates were similar (RR, 0.88; p=0.30). These results suggest thattransplantation from MUD and MRD donors produces similar survival for patients with AML.

Literatür Arşivi